Faculty Information - NISHIMURA Kouichi

（Last updated : 2026-10-02 14:25:58）

NISHIMURA Kouichi
Department School of Medicine(Tokyo Women's Medical University Adachi Medical Center), School of Medicine

Position Clinical Assistant Professor

■ Published papers

1.	Other	Effectiveness and safety of enfortumab vedotin plus pembrolizumab for patients aged 80 years and older with metastatic urothelial carcinoma: A multicenter retrospective study. 2026/08
2.	Original article	Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma. 2026/06/05
3.	Original article	Non-clear cell renal cell carcinoma has an immune-cold phenotype that affects response to immune checkpoint inhibitors. 2026/05/04
4.	Other	Increased risk of interstitial lung disease with enfortumab vedotin plus pembrolizumab compared with sequential enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in JAPAN. 2026/05
5.	Other	Prognostic impact of early C-reactive proteindynamics in advanced renal cell carcinoma treated with immune checkpoint inhibitor combinations. 2026/05
6.	Original article	Impact of first-line dual immuno-oncology combination therapy versus immuno-oncology plus tyrosine kinase inhibitor on outcomes of second-line VEGFR-TKI in advanced RCC: a real-world multi-institutional analysis. 2026/03
7.	Original article	Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma. 2026/01
8.	Original article	Efficacy and safety of nivolumab plus cabozantinib in octogenarian patients with advanced renal cell carcinoma. 2025/10
9.	Original article	A case of complete remission of bilateral upper tract carcinoma in situ following retrograde bacillus calmette–guérin (BCG) instillation via open- ended ureteral catheters after failure using Double- J stents. 2025/09/17
10.	Original article	Impact of polypharmacy on perioperative outcomes of robot‐assisted laparoscopic partial nephrectomy for small renal masses. 2025/09
11.	Original article	Long-term real-world outcomes of nivolumab plus ipilimumab for advanced renal cell carcinoma: a minimum of 4-years follow-up study. 2025/09
12.	Original article	Effect of age on treatment outcomes of first-line immune checkpoint inhibitor combination therapy for previously untreated advanced renal cell carcinoma. 2025/08
13.	Other	Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. 2025/05
14.	Original article	Comparative analysis of outcomes for patients with advanced renal cell carcinoma: Immuno-oncology era versus tyrosine kinase inhibitor era in the IMDC favorable-risk group. 2025/04
15.	Case report	Whole exome sequencing identified mutations of forkhead box I 1 (FOXI1), keratin 6 C (KRT6C) and gap junction protein delta 2 (GJD2) in a low-grade oncocytic tumor of the kidney: a case report. 2025/02
16.	Original article	Changes in outcome of patients with advanced non‑clear cell renal cell carcinoma from the tyrosine kinase inhibitor era to the immuno‑oncology era. 2024/11
17.	Original article	Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. 2024/09
18.	Original article	First‑line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the efectiveness using real‑world data. 2024/04
19.	Original article	Assessment of Feasibility of Robot-assistted Radical Cystectomy in Patients With Advanced Bladder Cancer Treated With Maintenance Hemodialysis Therapy 2022
20.	Case report	A case of metastatic Xp11.2 translocation renal cell carcinoma successfully managed by cytoreductive nephrectomy followed by axitinib therapy. 2017/05
Display 5 items
Display all(20)

■ Academic conference presentation

1.	Increased risk of interstitial lung disease with enfortumab vedotin plus pembrolizumab compared with sequential enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in JAPAN. （Poster notice，General） 2026/05/18
2.	Prognostic impact of early C-reactive protein dynamics in advanced renal cell carcinoma treated with immune checkpoint inhibitor combinations. （Poster notice，General） 2026/05/18
3.	Evaluation of PSA levels after prostatic urethral lift. （Speech，General） 2026/04/24
4.	Association between obesity and adverse events in nivolumab plus cabozantinib combination therapy for metastatic renal cell carcinoma. （Speech，General） 2026/04/23
5.	Prognostic impact of early C-reactive protein dynamics in advanced renal cell carcinoma treated with immune checkpoint inhibitor combinations. （Speech，General） 2026/04/23
6.	Immunotherapy outcomes and immune microenvironment profiles of patients with non-clear cell renal cell carcinoma. （Poster notice，General） 2025/09/26
7.	Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. （Poster notice，General） 2025/04/27
8.	Evaluation of robot-assisted radical cystectomy with intracorporeal ileal conduit for patients over 80 years of age （General） 2024/04/27
9.	Therapeutic efficacy of Cabozantinib or Axitinib rechallenge for advanced renal cell carcinoma. （Poster notice，General） 2024/04/27
10.	The retrospective study of upfront cytoreductive nephrectomy for metastatic renal cell carcinoma. （Poster notice，General） 2024/04/25
11.	Investigation of robotic assisted radical prostatectomy in our hospital. （Poster notice，General） 2020/12/22
12.	Clinical and pathological analysis of chronic vascular rejection after renal transplantation. （Speech，General） 2018/07/21
Display 5 items
Display all(12)